论文部分内容阅读
变活霉素A为一新的蒽环类广谱抗病毒抗生素,在组织培养内对4株单纯疱疹Ⅰ型病毒(HSV-1),4株单纯疱疹Ⅱ型病毒,流感甲_3病毒及柯萨奇B_6病毒的致细胞病变作用均有抑制活性,IC_(50)为6.25～12.5μg/ml。相同剂量可降低HSV-1繁殖量 1.5～3.5个对数值(log10)。细胞感染HSV-1后 4～10小时再用变活霉素A处理,仍可抑制,推迟细胞病变的发展.250～500μg/ml变活霉素A在无细胞系统内对HSV-2 DNA聚合酶,人免疫缺陷病毒(HIV-1)逆转录酶,鸭乙型肝炎病毒DNA聚合酶及牛胸腺DNA聚合酶α均无抑制活性。
As a new anthracycline broad-spectrum antiviral antibiotic, survivin A is a novel anthracycline-based broad-spectrum antiviral antibiotic. Four strains of herpes simplex virus type 1 (HSV-1), 4 herpes simplex virus type 2, Coxsackie B_6 virus induced cytopathic effect were inhibited, IC 50 (50) 6.25 ~ 12.5μg / ml. The same dose can reduce HSV-1 reproduction 1.5 to 3.5 log (log10). The HSV-2 DNA could be inhibited and delayed in 4 to 10 hours after infection with HSV-1, and still could inhibit and delay the development of cytopathic effect. HSV-2 DNA was polymerized in the cell-free system from 250 to 500 μg / ml of survivin A Enzyme, human immunodeficiency virus (HIV-1) reverse transcriptase, duck hepatitis B virus DNA polymerase and bovine thymus DNA polymerase alpha have no inhibitory activity.